Â Â Â UNITED STATESSECURITIES AND EXCHANGE COMMISSIONWASHINGTON, D.C. 20549Â Â Â FORMÂ 6-KÂ Â Â REPORT OF FOREIGN PRIVATE ISSUERPURSUANT TO RULE 13a-16 OR 15d-16UNDER THE SECURITIES EXCHANGE ACT OF 1934Â For the Month of DecemberÂ 2024Â Commission File Number: 001-38097Â Â Â ARGENX SE(Translation of registrantâ€™s name into English)Â Â Â Laarderhoogtweg 251101 EB Amsterdam, the Netherlands(Address of principal executive offices)Â Â Â Indicate by check mark whether the registrant files or will file annualreports under cover of FormÂ 20-F or FormÂ 40-F.Â FormÂ 20-FÂ Â xÂ Â Â Â FormÂ 40-FÂ Â Â¨Â Indicateby check mark if the registrant is submitting the FormÂ 6-K in paper as permitted by Regulation S-T RuleÂ 101(b)(1):Â Â¨Â Indicateby check mark if the registrant is submitting the FormÂ 6-K in paper as permitted by Regulation S-T RuleÂ 101(b)(7):Â Â¨Â Â Â Â Â Â Â Â EXPLANATORY NOTEÂ On DecemberÂ 27, 2024, argenx SE (the â€œCompanyâ€)issued a press release, a copy of which is attached hereto as ExhibitÂ 99.1 and is incorporated by reference herein.Â The information contained in this Current Reporton FormÂ 6-K, including ExhibitÂ 99.1, shall be deemed to be incorporated by reference into the Companyâ€™s Registration Statementson Forms F-3 (File No.Â 333-258251) and S-8 (File Nos.Â 333-225375,Â 333-258253, and 333-274721), and to be part thereof fromthe date on which this Current Report on FormÂ 6-K is filed, to the extent not superseded by documents or reports subsequently filedor furnished.Â Â Exhibit Â Description Â Â Â 99.1 Â Press Release DecemberÂ 27, 2024 Â Â Â Â SIGNATURESÂ Pursuant to the requirements of the SecuritiesExchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.Â Â ARGENX SE Â Â Â Date: DecemberÂ 27, 2024 By: Â /s/ Hemamalini (Malini) Moorthy Â Â Name: Hemamalini (Malini) Moorthy Title: General Counsel Â Â Â Exhibit 99.1Â Â argenx Announces Approval of VYVDURA (efgartigimodalfa and hyaluronidase-qvfc) in Japan for Adults with Chronic Inflammatory Demyelinating PolyneuropathyÂ VYVDURAÂ®now approved for at-home self-injection in Japan for both generalized myasthenia gravis and CIDPÂ argenx'sVYVGARTÂ® and VYVDURA portfolio approved in Japan for three indications â€“ first country globallywith access across three indicationsÂ DecemberÂ 27, 2024, 7:00 AM CETÂ Amsterdam,the Netherlands â€“ argenx SE (EuronextÂ & Nasdaq: ARGX), a global immunology company committed to improving thelives of people suffering from severe autoimmune diseases, today announced that Japanâ€™s Ministry of Health, Labour and Welfare (MHLW)approved VYVDURA for adults with chronic inflammatory demyelinating polyneuropathy (CIDP). VYVDURA is approved for CIDP as a once weekly30-to-90 second subcutaneous injection, which can be self-administered at home, and is the first and only neonatal Fc receptor (FcRn)blocker approved for the treatment of CIDP.Â â€œCIDP is a rare and debilitating diseasefor which there has been little innovation in treatment in 30 years,â€ said Luc Truyen, M.D., Ph.D., Chief Medical Officer of argenx. â€œWith VYVDURA, CIDP patients in Japan now have access to a novel therapy with a focused mode of action offering a convenient 30-to-90second at-home self-injection option with an established efficacy and safety profile, as demonstrated by the ADHERE trial and real-worldevidence. By extending the reach of this transformational therapy to thousands more patients, argenx continues to bring efgartigimod,our first-in-class FcRn blocker, to more patients in Japan and around the world suffering from severe autoimmune disease.â€Â CIDP is a progressive, immune-mediated rare anddebilitating neuromuscular disorder of the peripheral nervous system. Patients experience a range of disabling mobility and sensory issues,including trouble standing from a seated position, pain and fatigue, and frequent tripping or falling. Many patients become wheelchairbound and are unable to work as the disease progresses. Currently, 85% of patients require ongoing treatment and nearly 88% of treatedpatients experience residual impairment and disability.Â The MHLW approval is based on the ADHEREÂ Study,the largest clinical trial to date studying CIDP. In the ADHERE study, 69% (221/322) of patients treated with VYVDURA, regardless of priortreatment, demonstrated evidence of clinical improvement, including improvements in mobility, function and strength. ADHERE met its primaryendpoint ($p<0.0001$) demonstrating a 61% reduction (HR: 0.39 95% CI: 0.25; 0.61) in the risk of relapse versus placebo. Ninety-ninepercent of trial participants elected to participate in the ADHERE+ open-label extension. The safety results were generally consistentwith the known safety profile of VYVDURA in previous clinical studies and real-world use.Â VYVDURA was approved by the MHLW for manufacturingand marketing in JanuaryÂ 2024 and launched in AprilÂ 2024 for the treatment of generalized myasthenia gravis (gMG). In MarchÂ 2024,VYVDURA was designated as an Orphan Drug for the treatment of CIDP by the MHLW.Â Â Â Â Â SeeFDA-approved Important Safety Information below and fullÂ Prescribing InformationÂ for VYVDURA, which is marketed as VYVGARTHytrulo in the United States, for additional information.Â What is VYVGARTÂ® HYTRULO (efgartigimodalfa and hyaluronidase-qvfc)?Â VYVGART HYTRULO is a prescription medicine usedfor the treatment of adult patients with chronic inflammatory demyelinating polyneuropathy (CIDP).Â IMPORTANT SAFETY INFORMATIONÂ Do not use VYVGART HYTRULO if you have a seriousallergy to efgartigimod alfa, hyaluronidase, or any of the other ingredients in VYVGART HYTRULO. VYVGART HYTRULO can cause serious allergicreactions and a decrease in blood pressure leading to fainting.Â VYVGART HYTRULO may cause serious side effects,including:Â Â·Infection. VYVGART HYTRULO may increase the risk of infection. The most common infections for efgartigimodalfa-fcab-treated patients were urinary tract and respiratory tract infections. Signs or symptoms of an infection may include fever, chills,frequent and/or painful urination, cough, pain and blockage of nasal passages/sinus, wheezing, shortness of breath, fatigue, sore throat,excess phlegm, nasal discharge, back pain, and/or chest pain.Â·Allergic Reactions (hypersensitivity reactions). VYVGART HYTRULO can cause allergic reactions suchas rashes, swelling under the skin, and shortness of breath. Hives were also observed in patients treated with VYVGART HYTRULO. Seriousallergic reactions, such as trouble breathing and decrease in blood pressure leading to fainting have been reported with efgartigimodalfa-fcab.Â·Infusion-Related Reactions. VYVGART HYTRULO can cause infusion-related reactions. The most frequentsymptoms and signs reported with efgartigimod alfa-fcab were high blood pressure, chills, shivering, and chest, abdominal, and back pain.Â Tell your doctor if you have signs or symptomsof an infection, allergic reaction, or infusion-related reaction. These can happen while you are receiving your VYVGART HYTRULO treatmentor afterward. Your doctor may need to pause or stop your treatment. Contact your doctor immediately if you have signs or symptoms of aserious allergic reaction.Â Before taking VYVGART HYTRULO, tell your doctorif you:Â Â·take any medicines, including prescription and non-prescription medicines, supplements, or herbal medicines,Â·have received or are scheduled to receive a vaccine (immunization), orÂ·have any allergies or medical conditions, including if you are pregnant or planning to become pregnant,or are breastfeeding.Â What are the common side effects of VYVGARTHYTRULO?Â The most common side effects in efgartigimod-alfa-fcab-treatedpatients were respiratory tract infection, headache, and urinary tract infection. Additional common side effects with VYVGART HYTRULOare injection site reactions, including rash, redness of the skin, itching sensation, bruising, pain, and hives.Â Â Â Â Â These are not all the possible side effects ofVYVGART HYTRULO. Call your doctor for medical advice about side effects. You may report side effects to the US Food and Drug Administrationat

1-800-FDA-1088.Â Please see the full Prescribing Informationfor VYVGART HYTRULO and talk to your doctor.Â About ADHERE Trial DesignÂ The ADHERE trial was a multicenter, randomized,double-blind, placebo-controlled trial evaluating VYVDURAÂ® (efgartigimod alfa and hyaluronidase-qvfc) for the treatmentof chronic inflammatory demyelinating polyneuropathy (CIDP). ADHERE enrolled 322 adult patients with CIDP who were treatment naÃ¯ve(not on active treatment within the past six months or newly diagnosed) or being treated with immunoglobulin therapy or corticosteroids.The trial consisted of an open-label Stage A followed by a randomized, placebo-controlled Stage B. In order to be eligible for the trial,the diagnosis of CIDP was confirmed by an independent panel of experts. Patients entered a run-in stage, where any ongoing CIDP treatmentwas stopped and in order to be eligible for Stage A had to demonstrate active disease, with clinically meaningful worsening on at leastone CIDP clinical assessment tool, including INCAT,Â I-RODS, or mean grip strength. Treatment naÃ¯ve patients were able to skipthe run-in period with proof of recent worsening. To advance to Stage B, patients needed to demonstrate evidence of clinical improvement(ECI) with VYVDURA. ECI was achieved through improvement of the INCAT score, or improvement on I-RODS or mean grip strength if thosescales had demonstrated worsening during the run-in period. In Stage B, patients were randomized to either VYVDURA or placebo for upto 48 weeks. The primary endpoint was measured once 88 total relapses or events were achieved in Stage B and was based on the hazardratio for the time to first adjusted INCAT deterioration (i.e. relapse). After Stage B, all patients had the option to roll-over to anopen-label extension study to receive VYVDURA.Â About VYVDURAÂ VYVDURA is a subcutaneous combination of efgartigimodalfa, a human IgG1 antibody fragment marketed for intravenous use as VYVGART, and recombinant human hyaluronidase PH20 (rHuPH20), Halozymeâ€™sENHANZEÂ®Â drug delivery technology to facilitate subcutaneous injection delivery of biologics. In binding to the neonatalFc receptor (FcRn), VYVDURA results in the reduction of circulating IgG. It is the first-and-only approved FcRn blocker administeredby subcutaneous injection for the treatment of CIDP.Â VYVDURA is the proprietary name in Japan for subcutaneousefgartigimod alfa and recombinant human hyaluronidase PH20. It is marketed under different proprietary names in other regions.Â About Chronic Inflammatory Demyelinating PolyneuropathyÂ Chronic inflammatory demyelinating polyneuropathy(CIDP) is a rare and serious autoimmune disease of the peripheral nervous system. Although confirmation of disease pathophysiology isstill emerging, there is increasing evidence that IgG antibodies play a key role in the damage to the peripheral nerves. People with CIDPexperience fatigue, muscle weakness and a loss of feeling in their arms and legs that can get worse over time or may come and go. Thesesymptoms can significantly impair a personâ€™s ability to function in their daily lives. Without treatment, one-third of people livingwith CIDP will need a wheelchair.Â Â Â Â Â About argenxÂ argenxis a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases. Partnering with leadingacademic researchers through its Immunology Innovation Program (IIP), argenx aims to translate immunology breakthroughs into a world-classportfolio of novel antibody-based medicines. argenx developed and is commercializing the first approved neonatal Fc receptor (FcRn) blockerin the U.S., Japan,Â Israel, the EU, the UK, Canada and China. The Company is evaluating efgartigimod in multiple serious autoimmunediseases and advancing several earlier stage experimental medicines within its therapeutic franchises. For more information, visitÂ www.argenx.comÂ andfollow us onÂ LinkedIn,Â Twitter,Â andÂ Instagram.Â ContactsÂ Media:Â Ben PetokBpetok@argenx.comÂ Investors:Â AlexandraRoy (US)Â aroy@argenx.comÂ Lynn Elton(EU)Â lelton@argenx.comÂ Â Â